Health Care/Hospital

Advanced Aesthetic Technologies, Inc. is pleased to announce the approval of Algeness® VL agarose facial injection filler for marketing in China

AAT announces additional significant updates RADNOR, Pa., Jan. 29, 2025 /PRNewswire/ -- Advanced Aesthetic Technologies, Inc. ("AAT") announced today that their partner inChina has obtained approval to market their unique dermal filler Algeness® VL agarose facial injection filler, a 2.5% agarose...

2025-01-29 14:00 1521

Athinoula A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital Chooses a United Imaging Next Generation PET/CT to Revolutionize the Study of Systems Physiology

HOUSTON, Jan. 28, 2025 /PRNewswire/ -- As pioneers in biomedical imaging and neuroscience, the researchers at the Athinoula A. Martinos Center for Biomedical Imaging atMassachusetts General Hospital (MGH), a founding member of the Mass General Brigham healthcare system, have long appreciated the ...

2025-01-28 22:00 1969

Bloomage Joins the United Nations Global Compact

PARSIPPANY, N.J., Jan. 27, 2025 /PRNewswire/ -- Bloomage, a global leader in hyaluronic acid and other bioactive innovations, officially joined the United Nations Global Compact (UNGC). This commitment further reflects Bloomage's on-going efforts in global sustainable development.

2025-01-27 21:00 1397

CStone Partners with SteinCares to Market Sugemalimab in Latin America

* CStone will receive upfront, regulatory and commercial milestone payments, and book revenue from SteinCares through the supply of sugemalimab in 10 Latin American (LATAM) countries. * This marks CStone's third major global commercialization partnership for sugemalimab, with additional deals...

2025-01-27 12:30 1607

Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA

HONG KONG, Jan. 26, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been accepted by the Center for Drug Evaluation (CDE) of the N...

2025-01-27 09:53 1719

Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer

SYDNEY, Jan. 24, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the U...

2025-01-24 22:02 3519

Nuevocor Welcomes Andreas Wallnöfer as Chairman of the Board of Directors

SINGAPORE and PHILADELPHIA, Jan. 24, 2025 /PRNewswire/ -- Nuevocor , an IND-stage biotechnology company dedicated to developing functional cures to treat cardiomyopathies with aberrant mechanobiology, today announces the appointment ofDr. Andreas Wallnöfer as Chairman ...

2025-01-24 22:00 3473

Akluer Celebrates 520 Dual-Sided Treadmill Milestone with Customer Appreciation Day

NEW YORK, Jan. 24, 2025 /PRNewswire/ -- Akluer , the global leader in innovative fitness solutions, is excited to announce that its revolutionary 520 Dual-Sided Treadmill has sold over 5,000 u...

2025-01-24 22:00 3511

NUS researchers pioneer DNA-tagged gold nanoparticles for targeted cancer treatment

Using DNA barcoding, the novel technique tracks and optimises gold nanoparticles for precise drug delivery to tumours, advancing cancer therapies that are safer and more effective SINGAPORE, Jan. 24, 2025 /PRNewswire/ -- A team of researchers from the National University of Singapore (NUS) has d...

2025-01-24 15:55 2185

Kexing Biopharm Participates in the 17th Biotech Showcase, with Multiple Innovation Pipelines Gaining Attention

SHENZHEN, China, Jan. 24, 2025 /PRNewswire/ -- From January 13 to 16, Dr. Huiming Li, Deputy General Manager of Kexing Biopharm New Drug Research Center, attended the 17th Biotech Showcase Conference inSan Francisco and the Global Biopharma Symposium hosted by Jones Day & MSQ Ventures. The Jones...

2025-01-24 14:59 1979

Datasea Announces Continued Expansion with Agreements to Place its Acoustic High-Tech Products in an Additional 200 Beauty Stores in Northern China

With the New Agreements, Products to be Placed in a Total of 463 New Stores with  Total Projected Sales of 260,000 Units and Revenue of $19 Million  Expected by Year End 2025 BEIJING, Jan. 23, 2025 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS), a Nevada -based digital technology company specializing...

2025-01-23 22:30 3383

Lunit AI Enhances Precision in Predicting Outcomes for HER2-Targeted Therapy in Metastatic Colorectal Cancer - new study published in JCO Precision Oncology

Newly published study in collaboration with Japan's NCCHE reveals how AI-powered HER2 and tumor microenvironment analysis improves patient stratification and clinical outcome predictions SEOUL, South Korea, Jan. 23, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered sol...

2025-01-23 22:00 2973

Cadonilimab (PD-1/CTLA-4) Phase III Data for First Line Treatment of Advanced Gastric Cancer Published in Nature Medicine

HONG KONG, Jan. 22, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company")is excited to announce that the prestigious medical journal Nature Medicine published the results of the company's independently developed PD-1/CTLA-4 bispecific antibody cadonilimab in combination with oxali...

2025-01-23 08:31 1830

Health In Tech Announces Innovative Collaboration with MARPAI and Vitable DPC to Offer Competitive Quotes in Enhanced Self-Funded Solutions

STUART, Fla., Jan. 22, 2025 /PRNewswire/ -- Health In Tech, an Insurtech platform company backed by third-party AI technology, is thrilled to announce a new strategic collaboration with Vitable and MARPAI. This collaboration aims to introduce a competitively priced self-funded health plan

2025-01-23 06:00 3378

GI Innovation-LaNova Medicines Signs MOU for GI-102 + ADC Pancreatic Cancer Combination Therapy

SEOUL, South Korea, Jan. 22, 2025 /PRNewswire/ -- GI Innovation  (KQ:358570) announced that it signed a Memorandum of Understanding (MOU) with LaNova Medicines (LaNova) for the development of GI-102 and ADC pancreatic cancer combination therapy.

2025-01-22 21:00 2313

L&C Bio Secures World's First NMPA Approval for 'MegaDerm Plus' in China

SEONGNAM-SI, South Korea, Jan. 22, 2025 /PRNewswire/ -- L&C Bio (CEO Hwan-Chul Lee) has achieved a significant milestone in its global market strategy by becoming the first company worldwide to secure approval fromChina's National Medical Products Administration (NMPA) for its acellular dermal ma...

2025-01-22 20:30 2264

Smartee Unveils Eco Initiatives at New 100,000 sqm Clear Aligner Factory

SHANGHAI, Jan. 22, 2025 /PRNewswire/ -- Sustainability meets innovation as Smartee Denti-Technology announces the launch of its 100,000 sqm clear aligner factory. Equipped with advanced emissions control, solar energy initiatives, and water recycling systems, the facility reflects Smartee's commi...

2025-01-22 17:41 1710

Samsung Biologics reports fourth quarter and fiscal year 2024 financial results

* Recorded Q4'24 consolidated revenue of KRW 1.26 trillion * Recorded FY'24 consolidated revenue of KRW 4.55 trillion * Poised for further growth with expanded capacity and new service offerings INCHEON,South Korea, Jan. 22, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a globa...

2025-01-22 15:06 1534

Akeso Received Payment for the Development Collaboration on Tagitanlimab

HONG KONG, Jan. 22, 2025 /PRNewswire/ -- On January 22, 2025, Akeso Inc. (9926.HK) announced that it had received payment from Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. ("Sichuan Kelun") for their collaboration on the development of tagitanlimab, an innovative humanized monoclona...

2025-01-22 14:57 2854

Hyundai ADM Unveils a "New Paradigm in Cancer Treatment" - Preclinical Study Shows Promise for Continuous Oral Chemotherapy with Lowered Side Effects Risks

SEOUL, South Korea, Jan. 22, 2025 /PRNewswire/ -- Hyundai ADM Bio (Co-CEOs Taek-Sung Kim and Kwang-Hee Kim) announced the results of its preclinical study on the oral anti-cancer drug OTX-M, developed from the well-known injectable chemotherapy drug docetaxel, at the "Biotech Showcase 2025" held ...

2025-01-22 14:43 1572
12345 ... 284